EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V

View source ↗

Summary

EMA authorises Noxafil (posaconazole) for multiple fungal infections including candidiasis, mycoses, coccidioidomycosis, and aspergillosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis
• Coccidioidomycosis
• Mycoses

Drugs mentioned

• NOXAFIL (POSACONAZOLE)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Mycoses;Coccidioidomycosis;Aspergillosis. MAH: Merck Sharp and Dohme B.V. Decision date: 05/03/2026